| LBEPC21 | HIV transmission clusters in Zambia are smaller than in Europe: evidence from the HPTN-071 (PopART) study, BEEHIVE study, and individual-based models | E-poster | Surveillance: Measuring the HIV epidemic |
| LBEPB20 | T-cell responses induced by HTI vaccines and vesatolimod correlate with improved control of HIV rebound | E-poster | Other strategies and therapies |
| LBEPB19 | Factors associated with COVID-19 vaccination uptake amongst PLHIV in southern Nigeria | E-poster | SARS-CoV-2, COVID-19 and HIV |
| LBEPB18 | Anti-PD-L1 antibody ASC22 in combination with chidamide potentiates HIV latency reversal and immune function from ART-suppressed individuals: a single center, single-arm, phase 2 study | E-poster | Other strategies and therapies |
| LBEPB17 | Analytical treatment interruption among African women and Peruvian men & transgender individuals with early ART initiation +/- VRC01 circulating at HIV acquisition: early observations of viral rebound & control | E-poster | Other strategies and therapies |
| LBEPB16 | HIV drug resistance profile in clients experiencing treatment failure after the transition to a dolutegravir-based, first-line antiretroviral treatment regimen in Mozambique | E-poster | ART resistance |
| LBEPB15 | Neural tube defects and major external structural abnormalities by antiretroviral treatment regimen in Botswana: 2014-2022 | E-poster | Antiretroviral therapies and clinical issues in infants, children and adolescents |
| LBEPB14 | Epidemiological and clinical features of mpox in adults aged greater than 50 years in the United States of America, May 2022–April 2023 | E-poster | HIV and ageing |
| LBEPB13 | Week-96 results of ALLIANCE, a phase 3, randomized, double-blind study comparing bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) versus dolutegravir + emtricitabine/tenofovir disoproxil fumarate (DTG+F/TDF) in treatment-naïve people with both HIV-1 and hepatitis B | E-poster | Co-infections (including opportunistic infections) |
| LBEPB12 | Evaluation of incident hypertension and blood pressure changes among people living with HIV-1 (PLWH) receiving dolutegravir (DTG)-based regimens or comparator antiretroviral therapy (CAR) in randomized clinical trials through 96 weeks | E-poster | Clinical complications of HIV and antiretroviral therapy |